The company has collected a citizen petition stating that PICO is second-in-class compared to Kalypto’s first-in-class NPD, although Kalypto’s attorneys have said that they don’t know specifics of Smith & Nephew’s clearance submission.
Kalypto has asked the FDA to ensure a thorough review of Smith & Nephew’s process, standards and performance data, including that PICO is compared to NPD.
Related Articles on Smith & Nephew:
Smith & Nephew Signs Distribution Agreement With Injectable Bone Void Filler Company
Smith & Nephew Acquires TENET Medical Engineering
Smith & Nephew Patent Dispute With Arthrex Continues in Oregon
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
